Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover

被引:17
作者
Schlemmer, A
Ravn, P
Hassager, C
Christiansen, C
机构
[1] Ctr. for Clinical and Basic Research, DK-2750 Ballerup
关键词
bone resorption; circadian rhythm; nasal calcitonin;
D O I
10.1016/S8756-3282(96)00307-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purpose of this study was to examine the effect of intranasal salmon calcitonin (sCT) administration (200 IE), given either in the morning (8:00) or evening (21:00), on the known circadian variation in biochemical markers of bone turnover. An open, placebo-controlled, randomized, crossover study, with three 24 h studies of blood samples drawn every third hour and urine collected in 3 h aliquots was undertaken. Subjects consisted of nine healthy postmenopausal women, aged 58 +/- 7 years. Urinary CrossLaps (a measure of bone resorption) was measured by ELISA and corrected for creatinine (Cr), Serum osteocalcin (sOC) was measured by radioimmunoassay (RIA). The first 24 h study was performed without intervention. Prior to this control study the participants were randomized to either morning (8:00) or evening (21:00) sCT (200 LE), sCT administrations were given 4-5 days prior to and during the second study, After a washing-out period of 2 weeks the participants were given 200 IE of sCT at the reverse time of the day 5 days prior to and during the third study. At all timepoints, urinary CrossLaps/Cr exhibited a significant (p < 0.001) circadian rhythm with its zenith in early morning and nadir in late afternoon. Both morning and evening administration of sCT significantly decreased the urinary excretion of CrossLaps/Cr approximately 3-6 h after administration with a subsequent rebound effect, sOC did not exhibit a significant circadian variation and was not affected by the calcitonin. The 24 h mean urinary CrossLaps/Cr and sOC remained unchanged. Both morning and evening sCT significantly decreased the urinary excretion of CrossLaps/Cr 3-6 h after administration, with a rebound effect approximately 12 h later. However, the present study does not indicate that neither evening nor twice-daily administration is superior to morning administration. (C) 1997 by Elsevier Science Inc.
引用
收藏
页码:63 / 67
页数:5
相关论文
共 34 条
[1]  
ALEXANDERSEN P, 1994, J BONE MINER RES S1, V9, pS190
[2]   THE EFFECT OF CALCIUM SUPPLEMENTATION ON THE CIRCADIAN-RHYTHM OF BONE-RESORPTION [J].
BLUMSOHN, A ;
HERRINGTON, K ;
HANNON, RA ;
SHAO, P ;
EYRE, DR ;
EASTELL, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (03) :730-735
[3]   APPLICATIONS OF AN ENZYME-IMMUNOASSAY FOR A NEW MARKER OF BONE-RESORPTION (CROSSLAPS) - FOLLOW-UP ON HORMONE REPLACEMENT THERAPY AND OSTEOPOROSIS RISK ASSESSMENT [J].
BONDE, M ;
QVIST, P ;
FLEDELIUS, C ;
RIIS, BJ ;
CHRISTIANSEN, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :864-868
[4]  
BONDE M, 1994, CLIN CHEM, V40, P2022
[5]   BONE TURNOVER IN POSTMENOPAUSAL OSTEOPOROSIS - EFFECT OF CALCITONIN TREATMENT [J].
CIVITELLI, R ;
GONNELLI, S ;
ZACCHEI, F ;
BIGAZZI, S ;
VATTIMO, A ;
AVIOLI, LV ;
GENNARI, C .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 82 (04) :1268-1274
[6]   NYCTOHEMERAL CHANGES IN BONE TURNOVER ASSESSED BY SERUM BONE GLA-PROTEIN CONCENTRATION AND URINARY DEOXYPYRIDINOLINE EXCRETION - EFFECTS OF GROWTH AND AGING [J].
EASTELL, R ;
SIMMONS, PS ;
COLWELL, A ;
ASSIRI, AMA ;
BURRITT, MF ;
RUSSELL, RGG ;
RIGGS, BL .
CLINICAL SCIENCE, 1992, 83 (03) :375-382
[7]   ABNORMALITIES IN CIRCADIAN PATTERNS OF BONE-RESORPTION AND RENAL CALCIUM CONSERVATION IN TYPE-I OSTEOPOROSIS [J].
EASTELL, R ;
CALVO, MS ;
BURRITT, MF ;
OFFORD, KP ;
RUSSELL, RGG ;
RIGGS, BL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (03) :487-494
[8]   EFFECTS OF CONTINUOUS AND CYCLIC NASAL CALCITONIN ADMINISTRATION IN OVARIECTOMIZED WOMEN [J].
FIORETTI, P ;
GAMBACCIANI, M ;
TAPONECO, F ;
MELIS, GB ;
CAPELLI, N ;
SPINETTI, A .
MATURITAS, 1992, 15 (03) :225-232
[9]   ASSESSMENT OF BONE-RESORPTION WITH A NEW MARKER OF COLLAGEN DEGRADATION IN PATIENTS WITH METABOLIC BONE-DISEASE [J].
GARNERO, P ;
GINEYTS, E ;
RIOU, JP ;
DELMAS, PD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (03) :780-785
[10]   TREATMENT OF SEVERE HYPERCALCEMIA WITH CALCITONIN [J].
HOSKING, DJ .
METABOLIC BONE DISEASE & RELATED RESEARCH, 1980, 2 (03) :207-212